Could Gum Disease Bacteria Play a Role in Alzheimer’s?

Stay connected to Greek City Times for Free on Google News
Click NOW

For decades, Alzheimer’s disease has been studied largely as a disorder of the brain. Increasingly, however, researchers have been looking somewhere less obvious for part of the story: the mouth.

At the centre of that research is Porphyromonas gingivalis, a bacterium strongly associated with chronic periodontitis, the inflammatory disease that damages the tissues and bone supporting the teeth. Scientists have detected the bacterium, and the toxic enzymes it produces, in the brains of people with Alzheimer’s disease. In animal experiments, infection with P. gingivalis has also produced changes associated with Alzheimer’s pathology.

The findings have opened an intriguing line of inquiry into whether chronic infection and inflammation might contribute to the development or progression of Alzheimer’s in some people. They have not established that gum disease causes Alzheimer’s, and attempts to translate the theory into treatment have so far produced mixed results. But seven years after one of the most influential studies brought the connection to wider attention, researchers are still pursuing it.

In 2019, a team led by Stephen Dominy published a study in Science Advances examining post-mortem brain tissue from people with Alzheimer’s disease. The researchers identified P. gingivalis and gingipains, toxic protein-cutting enzymes produced by the bacterium, in Alzheimer’s brains. Higher levels of the gingipains were associated with Alzheimer’s diagnosis and with proteins involved in the disease, including tau.

The researchers then infected mice orally with P. gingivalis. The bacterium reached the brain and was accompanied by increased production of amyloid-beta 1-42, one of the proteins that accumulates in the characteristic plaques seen in Alzheimer’s disease. Gingipains were also found to damage tau and neurons in laboratory and animal experiments.

It was a provocative result because it suggested a possible sequence connecting a common chronic infection with processes already known to occur in Alzheimer’s.

Periodontitis itself is not caused by a single organism. It develops within a complex microbial community, influenced by the immune system and other factors. But P. gingivalis is regarded as an important pathogen because it can disrupt that microbial environment and produce gingipains capable of damaging tissue and interfering with immune responses.

The biological argument is plausible. Inflamed gums can allow bacteria and bacterial products to enter the bloodstream. Researchers have proposed several routes by which P. gingivalis, its toxins or the inflammation it provokes could ultimately affect the brain, including changes to the blood-brain barrier and prolonged activation of immune cells within the nervous system. A 2026 review described P. gingivalis-driven systemic and neurological inflammation as a credible mechanism, while emphasising that much of the evidence remains preclinical or epidemiological rather than proof of causation in humans.

Human population studies have added another layer. A US National Institute on Aging analysis followed more than 6,000 people using data spanning as long as 26 years and found associations between periodontal disease, antibodies to oral bacteria including P. gingivalis, and subsequent Alzheimer’s disease and other dementias. The researchers were careful about what that meant. Observational studies can identify an association, but they cannot prove that one condition caused the other.

That distinction is especially important in Alzheimer’s research. People developing dementia may become less able to maintain their oral health, making severe gum disease a potential consequence as well as a possible contributor. Age, smoking, diabetes, cardiovascular health, socioeconomic factors and access to dental care can further complicate the relationship.

A systematic review of clinical evidence published in 2022 found moderate evidence for an association between oral bacteria and Alzheimer’s disease, with a particularly strong association when bacteria were detected in brain tissue. But the authors concluded that further research was needed to establish how, or whether, those organisms participate in the development of the disease.

The most revealing test of the theory came when researchers attempted to treat Alzheimer’s by targeting the bacterium itself.

Cortexyme developed COR388, later known as atuzaginstat, to block the gingipain enzymes produced by P. gingivalis. In the original animal experiments, gingipain inhibitors reduced bacterial levels in the brain, lowered amyloid-beta production and reduced neuroinflammation.

That early promise led to the GAIN trial, a Phase 2/3 study involving 643 people with mild to moderate Alzheimer’s disease. The result was considerably less straightforward.

Atuzaginstat failed to produce a statistically significant benefit on the trial’s two primary measures of cognition and daily functioning across the overall study population. Cortexyme reported encouraging results in a pre-specified subgroup of participants who had detectable P. gingivalis DNA in their saliva, but the improvement was not reproduced across both primary endpoints. The treatment was also associated with dose-related elevations in liver enzymes. In January 2022, the US Food and Drug Administration placed the Alzheimer’s programme on full clinical hold.

Rather than proving the infection theory, the trial left scientists with a more complicated question: could a microbial mechanism be relevant only to a particular subset of Alzheimer’s patients?

That possibility is now being investigated more directly.

In Australia, a Phase I study that began recruiting in 2026 is testing GPV381, an experimental immunotherapy developed by Melbourne biotechnology company Denteric. The trial is deliberately restricted to people with early Alzheimer’s disease who also have measurable P. gingivalis in their saliva. GPV381 is designed to stimulate antibodies against the bacterium’s gingipain toxins rather than inhibit the enzymes with a small-molecule drug.

The study is small, involving 10 participants, and its first purpose is to establish safety and determine whether the treatment produces the intended immune response. It is not yet a test of whether the therapy can slow Alzheimer’s. Recruitment is taking place in Melbourne, with the research supported by CUREator+ Dementia and Cognitive Decline and the Australian Government’s Medical Research Future Fund.

Another trial registered in the United States is recruiting people with mild to moderate Alzheimer’s who test positive for P. gingivalis infection to investigate another treatment directed at the bacterium.

The continuing interest matters because Alzheimer’s itself is unlikely to have one simple cause. Genetics, ageing, vascular health, immune activity, amyloid, tau and other biological processes all intersect, and different combinations may matter in different people. Infection could eventually prove to be one piece of that picture without being an explanation for every case.

Nor does the evidence mean that treating gum disease has been shown to prevent Alzheimer’s. Good oral health has clear benefits in its own right, but there is not yet evidence to tell patients that brushing, flossing or periodontal treatment will protect them from dementia.

What the research has done is make the boundary between dental and neurological health considerably harder to dismiss.

A bacterium best known for its role in diseased gums has now been traced through laboratory experiments, human brain tissue, epidemiological research and clinical trials. The first attempt to turn that connection into an Alzheimer’s drug did not deliver the hoped-for result. Yet the question it raised remains open: for at least some people, could part of the process that eventually damages the brain begin far beyond it?

Read also Athens to Host Advanced Olive Oil Sommelier Programme This November

Stay updated with the latest news from Greece and around the world on greekcitytimes.com.
Contact our newsroom to share your updates, stories, photos, or videos. Follow GCT on Google News and Apple News.